Though persistent expression of PD-L1 after AAV delivery is favorable for the treatment of a chronic disease like RA, there is still concern about overexpression of PD-L1 causing long-term immune response suppression once the arthritis is in remission. This evidence concerns the gene CD274 and arthritic joint disease.